Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $6.8333.

A number of analysts have commented on the stock. Wedbush initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Stifel Nicolaus decreased their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Finally, Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Laurion Capital Management LP boosted its holdings in Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after acquiring an additional 14,566 shares during the last quarter. 683 Capital Management LLC boosted its holdings in Pyxis Oncology by 69.9% in the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after acquiring an additional 366,910 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Pyxis Oncology by 22.0% in the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in Pyxis Oncology by 158.8% in the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after acquiring an additional 482,310 shares during the last quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS opened at $1.78 on Monday. Pyxis Oncology has a twelve month low of $0.97 and a twelve month high of $5.55. The company has a market capitalization of $112.76 million, a price-to-earnings ratio of -1.36 and a beta of 1.42. The firm has a 50-day moving average of $1.82 and a two-hundred day moving average of $2.06.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). As a group, research analysts predict that Pyxis Oncology will post -1.23 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.